|
Press Releases |
|
 |
|
Tuesday, July 2, 2024 |
|
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) |
Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug conjugate (ADC) due to ongoing portfolio prioritization efforts within Bristol Myers Squibb. more info >> |
|
Friday, June 28, 2024 |
|
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China |
China is the third country to launch LEQEMBI following the United States and Japan. more info >> |
|
Friday, June 21, 2024 |
|
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City |
Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo City, Tokyo, which the company has been commissioned to conduct in order to raise awareness of dementia and promote early detection, and will continue the commission for this project in FY2024. more info >> |
|
Monday, June 10, 2024 |
|
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
Eisai Co., Ltd. and Biogen Inc. announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
Monday, June 3, 2024 |
|
Eisai Named to List of The Time 100 Most Influential Companies |
TIME reveals the TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world. more info >> |
|
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform |
Eisai Co., Ltd. announced today that the company decided to strengthen and continue its venture investment business, which launched in 2019, with the aim of discovering innovative technologies and services, supporting venture businesses with such technologies and partnering with those businesses in the future, so as to accelerate drug discovery innovation and the establishment of the ecosystem platform. more info >> |
|
Tuesday, May 28, 2024 |
|
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea |
Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (lecanemab) for treatment in adult patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD (early AD). more info >> |
|
Thursday, May 23, 2024 |
|
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024 |
Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4. more info >> |
|
Wednesday, May 22, 2024 |
|
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan |
Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate, "MTX"), in Japan. more info >> |
|
Wednesday, May 15, 2024 |
|
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
Global Crypto Leaders to Converge in Dubai for Historic 30th Edition of HODL
May 9, 2025 23:16 HKT/SGT
|
|
|
Nestle and OMP Showcase Approach to Future-Ready Supply Chain at Gartner Supply Chain Symposium/Xpo in Barcelona
May 9, 2025 22:00 HKT/SGT
|
|
|
UK Certifies Protector As First of Its Kind Remotely Piloted Aircraft
May 9, 2025 22:00 HKT/SGT
|
|
|
ZA Miner Expands Cloud Mining Platform with Clean Energy Infrastructure and Increased Global Adoption
May 9, 2025 20:00 HKT/SGT
|
|
|
Mitsubishi Heavy Industries Achieves Highest-Ever Order Intake, Revenue, Net Income, and Free Cash Flow in FY2024, Increases Dividends, and Releases FY2025 Guidance
May 9, 2025 18:57 JST
|
|
|
Valuufy Selected by Global Tech Leader for Environmental Impact Assessment
May 9, 2025 18:00 JST
|
|
|
Guangzhou Electrical Building Technology 2025 brings industry leaders together to shape a low-carbon, intelligent building future
May 9, 2025 17:00 HKT/SGT
|
|
|
DigiTech ASEAN Thailand Returns this November as Demands for Digital and AI-Driven Solutions Grow
May 9, 2025 16:45 HKT/SGT
|
|
|
Thailand, Led by DPM Prasert, to Showcase Leadership in Hosting the 3rd UNESCO Global Forum on the Ethics of AI 2025
May 9, 2025 15:30 HKT/SGT
|
|
|
Mazda Adopts North American Charging Standard for BEVs launched in Japan
May 9, 2025 16:03 JST
|
|
|
Solar & Storage Live Philippines 2025 Powers Up to Drive the Nation's Clean Energy Future
May 9, 2025 14:28 HKT/SGT
|
|
|
Ensign InfoSecurity Recognised in MITRE's 2024 Impact Report for Contribution to Global Cyber Defence Research
May 9, 2025 11:00 HKT/SGT
|
|
|
Unlocking the Full Potential of GCCs: The Strategic Power of Cultural Integration
May 9, 2025 02:53 HKT/SGT
|
|
|
India: Revolutionizing Video And Content For The Global Media And Entertainment Industy
May 9, 2025 02:14 HKT/SGT
|
|
|
The 33rd China Cycle 2025 Grandly Commences
May 8, 2025 17:00 HKT/SGT
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|